MCL1 and acute myeloid leukemia: Our data therefore favor the interpretation that bortezomib-induced stabilization of antiapoptotic Mcl1 is counteracted by a concomitant (also bortezomib-induced) modification into a proapoptotic derivative, which keeps AML cells susceptible to therapy.